GRIA2 and myeloid sarcoma: Third, a greater level of GluR2–GAPDH complexes are detected in MS plaques [123], and disruption of the GluA2-GAPDH complex has been shown to produce a therapeutic/protective action in EAE [123] (see Section 2.3 for a related discussion on this topic).